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ABSTRACT
High-mobility group protein B1 (HMGB1) has been implicated in numerous tumour 
types where expression regulates tumour cell growth and survival. We hypothesised 
that high HMGB1 expression in ovarian tumours would predict poor patient survival.
Using tissue microarrays of primary ovarian cancers combined with a 
comprehensive database of clinicopathological variables, the expression of HMGB1 
was assessed by immunohistochemistry in two independent cohorts (n=194 and 
n=360) using a monoclonal antibody specific for HMGB1.
Kaplan-Meier analysis showed an association of HMGB1 expression with 
progression free survival in the primary cohort (p=0.023). In the validation cohort, 
expression was associated with overall survival (p=0.002). Low expression of HMGB1 
was protective and in a multivariate model HMGB1 expression was shown to be an 
independent predictor of poor survival in ovarian cancer (p=0.006).
The role of HMGB1 in cancer is complex. As high levels of HMGB1 expression are 
likely to render ovarian cancer cells resistant to chemotherapy, therapies targeting 
the HMGB1 axis may be appropriate in the treatment of ovarian cancer patients.
INTRODUCTION
Ovarian cancer is the 5th most common cancer and the 
4th most common cause of female cancer deaths in the UK 
with a European age standardised incidence of approximately 
17 cases/100,000 women. Whilst survival from ovarian 
cancer has almost doubled over the last 30 years, the 5 year 
survival rate is still relatively poor at less than 50%. The 
incidence and mortality rate in women over the age of 65 
is notably higher (survival rate less than 30%) with patients 
typically presenting with Stage III/IV metastatic disease [1]. 
However, if detected at the earliest stages of development, 
90% of patients will survive. Therefore, it is vital that novel 
independent prognostic markers are identified in order to 
improve our understanding of ovarian cancer biology and 
the management of these patients.
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High-mobility group protein B1 (HMGB1) has 
recently been implicated in a number of human cancers 
including colon, gastric, lung, and liver (reviewed extensively 
in [2]. The role of HMGB1 (a chromatin binding protein) in 
processes relevant to cancer cell survival include autophagy 
[3, 4], genome stability [5], angiogenesis [6] and invasion 
and metastasis [7].
HMGB1 contains a long highly acidic C-terminal 
tail and two HMG box (A box and B box) domains 
which mediate DNA binding in a non-sequence specific 
manner [8]. It is the most ubiquitously expressed of the 
HMG family members and is able to translocate between 
the nucleus and cytoplasm [9]. HMGB1 has a complex 
range of functions depending in part on its subcellular and 
extracellular localisation, redox state, and interaction with 
cell surface receptors and transcription factors. Within 
the nucleus HMGB1 binds chromatin and is involved in 
DNA repair, replication, recombination, transcription and 
genomic instability. HMGB1 expression can regulate the 
mitochondrial bioenergetics of cancer cells by enhancing 
complex I activity, ATP production and subsequent 
proliferation and migration of tumour cells [10].
Of recent interest is the role of HMGB1 as a 
positive regulator of autophagy in cancer [11]. Autophagy 
is the process of maintaining cellular homeostasis under 
conditions of stress (i.e. hypoxia and increased genome 
instability) with the removal of unwanted/damaged 
cytosolic organelle contents into double membrane 
structures called autophagosomes. In cancer cells, stress 
induced autophagy acts in a cyto-protective manner 
preventing a shift to apoptotic cell death. During cellular 
stress HMGB1 translocates to the cytosol and binds 
beclin 1 which subsequently induces the formation of 
autophagosomes [12]. p53 is a known negative regulator 
of autophagy and is frequently mutated in ovarian cancer 
(with near universal mutation in the high grade serous 
subtype). Deficiency in p53 causes increased expression 
of cytosolic HMGB1 and enhanced autophagic flux [13].
The prognostic value of HMGB1 in ovarian cancer 
remains unclear. There is an important need to understand 
the context-dependent role of HMGB1 as either an anti- 
or pro-tumorigenic protein in ovarian cancer. To achieve 
this, the expression and prognostic value of HMGB1 was 
examined using ovarian cancer tissue microarrays from 
two independent cohorts. Both cohorts were analysed to 
determine the effect on survival and the utility of HMGB1 
as an independent prognostic marker.
RESULTS
HMGB1 protein expression is associated with 
progression free and overall survival in ovarian 
cancer cohorts
To determine whether the HMGB1 expression was 
associated with patient survival, we stained a primary 
(Nottingham) cohort comprised of 194 ovarian cancer cases 
using immunohistochemistry with a rabbit monoclonal 
antibody specific for endogenous HMGB1. The monoclonal 
antibody detected endogenous nuclear and cytoplasmic 
staining for HMGB1 (Figure 1). Of the 162 evaluable 
ovarian tumours stained, 35/162 (22%) had weak/absent 
staining and 127/162 (78%) had positive staining (cut point 
H-score >42 represented positive expression). Kaplan-
Meier survival analysis demonstrated that there was a 
statistically significant difference between patients that had 
high or low/absent expressing tumours and progression free 
survival (log rank test, p=0.023). There was also a trend 
with overall survival but it failed to reach significance in 
this primary cohort (p=0.077) (Figure 2).
This finding was expanded on in a validation cohort 
of 360 ovarian cancer cases with extensive clinical data. 
Of the 321 evaluable ovarian tumours stained with the 
HMGB1 specific monoclonal antibody, 43/321 (13%) 
had weak/absent staining and 278/321 (87%) had positive 
staining having dichotomised cases into high or low/
absent expressing groups. Kaplan-Meier survival analysis 
demonstrated an association with HMGB1 levels and 
overall survival for the validation cohort (log-rank test, 
p=0.002) (Figure 2). Weak/absent expression of HMGB1 
expression gave an almost 2 fold increase in survival 
time from 56 months to 104 months (Table 1). HMGB1 
expressing tumours resulted in a poor overall survival 
outcome.
HMGB1 expression is associated with tumour 
stage, histology, and the administration of 
adjuvant chemotherapy
Univariate analysis was performed on the validation 
cohort to determine whether HMGB1 expression was 
associated with standard clinicopathological variables 
(Table 2). Pearson’s χ2 or Fisher’s exact tests demonstrated 
that HMGB1 expression was associated with tumour stage 
(p=0.050), histological type (p<0.001) and the addition of 
adjuvant chemotherapy (p=0.002).
HMGB1 represents an independent prognostic 
marker in ovarian cancer
To determine whether HMGB1 represented an 
independent prognostic marker, Cox regression was 
performed (Table 3). HMGB1 was still associated with 
survival when stage, histology and adjuvant therapy 
were included as potentially confounding factors in a 
multivariate Cox regression (with individual Kaplan-Meier 
statistics of p<0.001, p<0.001 and p<0.033 respectively). 
In this multivariate model the histological tumour type 
(p=0.467) was no longer significant. However, HMGB1 
remained an independent prognostic factor (p=0.006, 
HR=1.921). In addition FIGO stage (p<0.001) and 
response to chemotherapy (p<0.001) also remained 
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independent predictors of patient survival suggesting that 
HMGB1 may be a useful independent prognostic marker 
in ovarian cancer.
DISCUSSION
To our knowledge this work represents the first 
large scale tissue microarray analysis of HMGB1 protein 
expression in multiple subtypes of ovarian cancer with 
replication in an independent second cohort. Our results 
indicate that high expression of HMGB1 is deleterious in 
ovarian cancer reducing the overall mean survival time 
(from 104 months in low/absent expressing tumours 
to 56 months in high expressing tumours). The role of 
HMGB1 in cancer is complex and is likely to be tumour 
cell specific as well as contingent on the redox state of 
HMGB1, its subcellular localisation and the expression 
of corresponding ligands/binding partners (reviewed in 
Kang et al, 2013). In our study, there was a trend towards 
HMGB1 expression being associated with overall survival 
in the primary cohort. However, HMGB1 expression was 
associated with progression free survival in the primary 
cohort. Indeed, our data support the results of a recent 
small scale study of ovarian cancer patients (n=74 patients) 
which confirmed that high HMGB1 tissue expression 
correlated with progression free survival [14]. We extend 
these observations by demonstrating that HMGB1 was 
associated with overall survival in our validation cohort.
The mechanism by which HMGB1 expression is 
deleterious for ovarian cancer patients is currently unclear. 
HMGB1 may play a role in the bioenergetic output of 
the tumour. Recent data in pancreatic cell lines suggests 
HMGB1 (in combination with one of its receptors RAGE) 
may regulate mitochondrial complex I activity, and 
Figure 1: Representative photomicrographs of ovarian TMA cores immunohistochemically stained for HMGB1 from 
Nottingham cohort (cut point >42).  The level of expression ranged from (A) Negative (H-score 0), (B) Weak (H-score 14), (C) 
Intermediate (H-score 167) and (D) Strong expression (H-score 213).
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Figure 2: Kaplan Meier curves showing overall survival in (A) the Derby cohort and (B) overall survival and (C) progression free survival 
in ovarian cancer patients in the Nottingham cohort.
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subsequent ATP production, with a resulting increase in 
cellular proliferation and migration [10]. However, to date 
no studies have explored how HMGB1 may regulate the 
bioenergetics of ovarian cancer cells and this will be a 
fruitful area for further investigation.
HMGB1 may play an important role in shifting the 
balance from apoptosis to autophagy. HMGB1 and wild 
type p53 regulate the expression of each other [15, 16]. 
Furthermore HMGB1 has been reported to form a complex 
with wild type p53 regulating the balance between apoptosis 
and autophagy [13]. In p53 deficient HCT116 cells cytosolic 
expression of HMGB1 is increased inducing autophagy. 
Therefore, HMGB1 promotes autophagy in the setting 
of diminished wild type p53. Although beyond the scope 
of this study, it will be important to determine whether 
expression of HMGB1 in ovarian cancer is associated with 
other markers of autophagy including LC3B and Beclin-1.
Our work has some limitations as we were unable to 
determine the relative proportions of HMGB1 in different 
subcellular compartments. Furthermore, our antibody 
reagent does not discriminate (to our knowledge) the 
different redox states of HMGB1 or acetylation status of 
HMGB1, all of which are known to influence HMGB1 
function [17, 18].
Our finding that HMGB1 expression levels in the 
validation cohort were associated with the administration 
of adjuvant chemotherapy and both remain independent 
prognostic markers after multivariate analysis is an 
interesting finding and has implications for therapy. 
Whilst our data indicates an association between HMGB1 
and administration of therapy, individual Kaplein-Meier 
statistics for the addition of chemotherapy indicate that 
in this cohort patients who received no chemotherapy had 
a better survival outcome than those that did (p=0.033 
data not shown). The reasons for this are unclear but may 
reflect the proportion of patients given chemotherapy 
between 1984 and 1997, with patients with a worse 
prognosis receiving this treatment. Patient numbers 
were insufficient for survival analysis grouping patients 
based on both chemotherapy and HMGB1 co-status. 
Nevertheless, our data indicates that HMGB1 is associated 
with poor prognosis in two cohorts spaced 10 years apart 
with different proportions treated with chemotherapy.
Previous in vitro experiments assessing 
chemosensitivity of ovarian cancer cells lines (to 
cisplatin) have shown that they are dependent on the 
BTP/POZ transcription family member NAC1 which 
induces autophagy [19]. Under stress (i.e. that induced by 
cytotoxic agents) NAC1 increases expression and cytosolic 
translocation of HMGB1. More cytosolic HMGB1 is then 
available to bind beclin-1 (and displace it from Bcl-2) 
and subsequently induce autophagy. NAC-1 knockdown 
Table 1: Mean survival time in relation to HMGB1 expression.
Expression
Mean survival time (months) in relation to HMGB-1 expression
Estimate (months) 95% confidence interval
Lower bound Upper bound P-value
Low 104.2 73.2 135.1
0.002High 55.7 45.4 65.9
Overall 63.7 53.2 74.1
Table 2: Univariate analysis of HMGB1 expression in association with standard clinicopathological variables and 
autophagy regulators using the χ2-or Fisher’s Exact test
Variable χ2-test (P-value)
HMGB1
SEER age 0.186*
Tumour FIGO stage 0.050*
Tumour grade 0.646*
Macroscopic residual disease 0.085
Adjuvant therapy 0.005*
Histological type <0.001
Abbreviation: FIGO=International Federation of Gynecology and Obstetrics
*Fishers exact test P-values <0.05 are accepted to be significant.
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experiments in ovarian cancer cell lines treated with 
cisplatin resulted in a reduction of cisplatin/HMGB1 
induced autophagy and an increase in cytotoxicity of 
ovarian cancer cells. Therefore, HMGB1 protects ovarian 
cancer cells from chemotherapy induced apoptosis by 
shifting the balance from apoptosis to autophagy [20].
Our work using two independent cohorts of ovarian 
cancer patients demonstrates that HMGB1 may represent 
an independent marker of poor prognosis. Supporting a role 
for HMGB1 as an independent prognostic marker, a study 
of HMGB1 serum levels in 105 ovarian carcinoma patients 
demonstrated that increased levels of HMGB1 were found 
in patients with more advanced stage disease and were at 
higher levels in cancer patients compared with healthy 
controls [21]. Therefore, future functional studies should 
determine the mechanism of HMGB1 function in ovarian 
cancer. If this can be determined, then strategies designed 
to modulate the HMGB1 pathway may provide a rational 
approach in the therapeutic targeting of ovarian cancer.
MATERIALS AND METHODS
Patient samples
This is a retrospective validation study with patients 
comprehensively staged according to the International 
Federation of Obstetricians and Gynecologists (FIGO) 
staging system for ovarian cancer. Full pathology review has 
been performed to current standards. Clinical details of both 
the Nottingham (primary cohort) (n=194) [22] and Derby 
(validation cohort) (n=360) [23] cohorts have been previously 
described (Supplementary Tables 1 and 2). This work was 
approved by the Derby Royal Hospital Ethics Committee and 
Nottingham Research Ethics Committee. In the compilation 
Table 3: Multivariate analysis for overall cancer specific survival in 309 consecutive patients with epithelial ovarian 
cancer
Exp(B) 95% CI for Exp (B) P-value
Lower Upper
FIGO stage
 Stage 1 1 <.001
 Stage 2 3.350 1.918 5.852
 Stage 3 7.886 4.896 12.704
 Stage 4 10.021 5.810 17.284
Histological type
0.467
Borderline 1
Clear cell OVCA 1.130 0.479 2.667
Mucinous OVCA 1.695 0.767 3.744
Endometrioid OVCA 1.339 0.606 2.962
Serous OVCA 1.594 0.796 3.195
Undifferentiated OVCA 1.598 0.761 3.354
Other OVCA 3.180 0.960 10.533
Adjuvant therapy
 No 1 <.001
 Yes 0.361 0.240 0.541
HMGB1
 Low 1 0.006
 High 1.921 1.205 3.064
Abbreviations: CI=confidence interval; FIGO=International Federation of Gynecology and Obstetrics.
The analysis is based on a Cox multivariate regression model. P-values <0.05 are accepted to be significant.
Oncotarget7www.impactjournals.com/oncotarget
of this manuscript, the Reporting Recommendations for 
Tumor Marker Prognostic Studies (REMARK) criteria, were 
followed throughout the study [24].
Nottingham University Hospitals cohort (Primary)
The cohort comprises 194 consecutive cases of 
ovarian epithelial cancer treated at Nottingham University 
Hospitals from 2000 to 2007. Survival was calculated 
from the operation date until 1st of October 2012 when 
any remaining survivors were censored.
Derby City Hospital cohort (Validation)
The cohort consisted of 360 consecutive ovarian 
epithelial cancer cases treated at Derby City Hospitals 
between 1st January 1984 and 31st December 1997. Survival 
was calculated from the operation date until 31 November 
2005 when any remaining survivors were censored. The 
database was audited to ensure validity; there were no major 
discrepancies with over 97% of data available.
Tissue microarray and immunohistochemistry
Tissue microarrays were constructed as described 
previously [22, 23, 25]. Antibodies were optimised on 
full faced sections. Positive and negative (omission of the 
primary antibody and replacement with IgG-matched serum) 
controls were included in each run. Immunohistochemical 
staining was performed using a routine streptavidin–
biotin peroxidase method. Tissue-array sections were first 
deparaffinised with xylene, rehydrated through graded 
alcohol and immersed in methanol containing 0.3% (v/v) 
hydrogen peroxide for 20 minutes. Antigen retrieval was 
achieved by immersing sections in pH 6.0 citrate buffer and 
heated in an 800W microwave for 10 minutes at high power 
and 10 minutes at low power. Endogenous avidin/biotin 
binding was blocked (avidin/biotin blocking kit, Vector 
Labs, Peterborough, UK), followed by addition of 100 μl 
1:5 normal swine serum (NSS) to Phosphate buffered saline 
(PBS) for 15 minutes to block non-specific binding.
Sections were incubated with a Rabbit anti-
HMGB1 mAb (clone D3E5) (New England Biolabs, 
Hitchin, UK). After washing with PBS, sections were 
incubated with 100 μl of biotinylated goat anti-mouse/
rabbit immunoglobulin (Dako Ltd, Ely, UK) diluted 
1:100 in NSS, for 30 minutes, washed in TBS and 
incubated with 100 μl of pre-formed streptavidin–biotin/
horseradish peroxidase complex (Dako) for 60 minutes. 
Visualisation was achieved using 3,3′-diaminobenzidine 
tetra hydrochloride (DAB, Dako), and then lightly 
counterstained with haematoxylin (Dako), dehydrated in 
alcohol, cleared in xylene, and mounted with distyrene, 
plasticiser and xylene (DPX–BDH, Poole, UK).
Evaluation of staining
Tumour microarray cores were imaged using a 
NanoZoomer (Hamamatsu, Bridgewater, NJ, USA). Image 
analysis was semi-automated using Aperio ImageScope 
v11.2.0.780 software. The positive pixel count v9.1 
algorithm settings were modified to provide accurate calling 
of expression levels (Iwp(high) at 140, Iwp(Low)=Ip (High) 
at 103 and Ip (low)=Isp(High) at 75). The accuracy of these 
settings to correctly call expression levels was confirmed 
by two experienced observers in the analysis of TMAs. 
Tumours were assigned a modified Histo-score (H-score) 
and assessed for high, low or negative HMGB1 expression. 
Observers were blind to clinical and pathological 
parameters. X-TILE software was employed to determine 
cut point selection values to segregate tumours into high 
and low/absent expressing groups [26].
Statistical analysis
Statistical analysis was performed using SPSS20 
statistical software (SPSS Inc., Chicago, IL, USA). 
Pearson's χ2-tests and Fisher’s exact tests were used 
to determine the significance of associations between 
categorical variables. Survival rates were calculated 
using the Kaplan–Meier method; differences between 
survival curves were tested using the log-rank test. The 
Cox proportional-hazards model was used for multivariate 
analysis in order to calculate the Hazard ratios and 
independent significance of individual factors. In all 
cases two-sided P-values of <0.05 were considered as 
statistically significant.
Abbreviations
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